Synthesis, Structural Elucidation, and Evaluation of Antimicrobial Activity of 5-Ethoxy-2-Mercaptobenzimidazole Derivatives

Alaa Alkhafaji¹, Zuhair Muhi-Eldeen²*, Elham Al-Kaissi¹, Najah Al-Muhtaseb², Tawfiq Arafat² and Mohammad A Ghattas³

¹ Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Petra, Amman, Jordan
² Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, University of Petra, Amman, Jordan
³ College of Pharmacy, Al-Ain University of Science and Technology, Al-Ain, UAE

*Corresponding e-mail: zeldeen@uop.edu.jo

ABSTRACT

Objective: The aim of this study was to design and synthesize new amino acetylenic 5-ethoxy-2-mercaptobenzimidazole derivatives as potential antimicrobial agents. Methods: New series of 5-ethoxy-2-{[4-(t-amino-1-yl) but-2-yn-1-yl] sulfanyl}-1H-benzimidazole derivatives were synthesized by Mannich reaction, and investigated for their antimicrobial activity. Their structural confirmation was confirmed using the EuroEA elemental analyzer, and by Bruker FTIR, 1H-NMR, 13C-NMR. The antimicrobial activity was evaluated in-vitro by agar diffusion method and broth dilution test. The minimum inhibitory concentration and the minimum bactericidal/fungicidal concentration were determined. Results: The IR, 1H-NMR, 13C-NMR and elemental analysis were consistent with the assigned structures. All new amino acetylenic 5-Ethoxy-2-mercaptobenzimidazole derivatives showed good antibacterial activity against Bacillus subtilis with minimum inhibitory concentration value of 31.25 µg/ml except 5-ethoxy-2-{[4-(2-methylpiperidin-1-yl) but-2-yn-1-yl]sulfanyl}-1H-benzimidazole which showed value of 250 µg/ml, 5-ethoxy-2-{{4-(2,6-dimethylpiperidin-1-yl)but-2-yn-1-yl]-sulfanyl}-1H-benzimidazole showed excellent antifungal activity against Candida albicans with the lowest minimum inhibitory concentration value of 31.25 µg/ml. Conclusion: The antimicrobial results promoted our interest to carry out further structural modifications, to enhance both antibacterial and antifungal activities, and their selectivity.

Keywords: 5-ethoxy-2-mercaptobenzimidazole, Aminoacetylenic, Mannich reaction, Alkylation

Abbreviations: MIC: Minimum Inhibitory Concentration; MBC: Minimum Bactericidal Concentration; MFC: Minimum Fungicidal Concentration; SD: Standard Deviation; MHB: MUELLER Hinton Broth; MHA: Mueller Hinton Agar; SDB: Sabouraud Dextrose Broth; SDA: Sabouraud Dextrose Agar

INTRODUCTION

The progression in the bacterial resistance against antibiotic therapy and the emerging new pathogens is becoming a critical problem. Antimicrobial agents are the drugs, chemicals, or other substances that kill or inhibit the growth of the microbes, they include antibacterial drugs, antiviral agents, antifungal agents, and anti-parasitic drug [1,2]. Researchers use different structures to discover, synthesize and develop new antibacterial and antifungal agents [3]. Benzimidazole is considered a remarkable heterocyclic compound that has significance in medicinal chemistry and biological activity, 2-Mercaptobenzimidazole (2-MBI) consist of benzimidazole moiety which is a bicycle compound, includes a benzene ring fused with imidazole ring containing 2 nitrogen atoms at 1, 3 positions and the 2-substituted benzimidazole with thiol group SH (mercapto) gives the compound the antibacterial and other biological activities [4]. Shet, et al., designed and synthesized new 2-substituted alkyl thioarylbenzimidazole derivatives, these compounds were screened for in-vitro antibacterial activity against gram positive bacteria Staphylococcus aureus (S. aureus) and Enterococcus fecalis (E. fecalis), gram negative bacteria Klebsiella and Escherichia coli (E. coli), and the activity was compared to ciprofloxacin as a control, in addition, their antifungal activity was evaluated by using (C. albicans and

A. niger) and the activity were compared to fluconazole as a control. The results showed that 2-MBI derivatives with substituents -Cl, -NO₂, -H on thioaryl moiety have remarkable antimicrobial activity against gram positive bacteria and excellent antifungal activity against fungi [5] (Figure 1).

![Figure 1 The structure of new 2-substituted alkyl thioarylbenzimidazole derivatives](image)

In a recent study synthesis of novel benzimidazole derivatives (Figure 2) is involved. These novel compounds were assessed for their antibacterial and antifungal activities. Against gram positive (S. aureus) and gram negative (E. coli) bacteria, the researchers concluded the antimicrobial activity was low when there was no substitution, while when there is chlorine and dimethyl amine on the aromatic ring the antimicrobial activity was high, regarding the antifungal activity against (C. albicans) the researchers found that the derivative possessing p-dimethyl amine substituent showed a higher antifungal activity than the others [6].

![Figure 2 The structure of novel benzimidazole derivatives](image)

In reviewing various structural features of different compounds under investigation as antimicrobials, the development of resistance, and selectivity, promoted our interest to synthesize amino acetylenic 5-ethoxy-2-mercaptobenzimidazole derivatives and investigate the role of the aminoacetylenic group on their antimicrobial activity. This will provide possibility to increase potency and decrease the resistance for the following reasons: the presence of sulfur group have a great contribution on the activity of the compounds due to hydrogen bonding or complexation, electrostatic interaction by the presence of 2-acetylenic group expected to enhance potency of the compounds against bacteria and fungi due to their overlap interaction with various sites in the microbes, in addition to their appropriate distance between 2-MBI and cyclic amine provide more binding sites with the microbes. The cyclic amine have several binding interaction such as, ionic interaction, improve lipophilicity, protonated nitrogen increases the compounds permeability through the outer membrane porins of gram negative bacteria and forms ionic bonding with their corresponding groups on receptors.

Benzimidazole is a heterocyclic group that varied from other heterocyclic such as oxazole or thiazole in affecting the antimicrobial activity. Benzimidazole showed their antibacterial activity by inhibiting the bacterial nucleic acid and protein synthesis, this ability of benzimidazole due to their structural similarities with the purine, the ethoxy group at 5-position expected to promote lipophilicity and activity [4,7]. The presence of these unique groups in our structure may provide a potent antimicrobial activity.

**MATERIALS AND METHODS**

**Experimental**

**Chemistry: Chemicals**

5-ethoxy-2-mercaptopbenzimidazole 97% (2-MBI), propargyl bromide, pyrolidine 99%, 2-methylpiperidin 98%,
1-methylpiperazine 99%, Cis-2, 6-dimethylpiperidine 98%, hexamethylenemine 99%, morpholine reagent plus 99%, all of them were purchased from (Sigma Aldrich, USA), potassium carbonate anhydrous (Gainland chemical company (GCC), UK), cuprous chloride (East Anglia Chemicals Hadleigh Ipswich), magnesium sulphate anhydrous (Lonover, UK), paraformaldehyde polymer (BDH chemicals Ltd Poole, England), acetonitrile 99.7% (PanReAc Quimca SA, EU), 1, 4-dioxane (FULL Time, China), acetone 99% (Scharlau, Spain), chloroform (TEDIA, USA), absolute ethanol 99.9% (Super Chem), distilled water (Ultra, Jordan), dimethyl sulfoxide (DMSO) (BBC Chemicals for lab, EU), diethyl ether (Lonover, England)/(RCL Labs can, Thailand).

**Instruments**

Analytical balance with a precision 0.01 mg (Phoenix instrument, USA), hot plate with magnetic stirrer (Dragon, China), rotary evaporator 0-100 Kpa/0-700 mmHg (Rocker 600, Germany), buchner funnel pump (Vacuubrand, Germany), gallenkamp melting point apparatus, bruker FT-IR spectrophotometer 7800 to 400 cm\(^{-1}\) (evisa, Poland), NMR 300 MHz (Varian 300 MHz, USA), NMR 500 MHz (Varian 500 MHz, USA), elemental analyzer with variation range (± 4%) (Euro Vector, Italy), balance (BoEco, Germany), autoclave machine (Rypa, Spain), incubator (EuroStar, UK), vortex mixer (Labinco, India), hot plate magnetic stirrer (Dragon, china), sterile tubes, sterile swabs (MWe, UK), micropipette (1 ml, 0.1 ml) (Oxford, USA).

**Molecular Docking**

The DHFR crystal structure was obtained from the protein data bank (PDB ID: IDFR) and was used in this docking study [8,9]. The DHFR structure was checked for any missing atoms or residues via the protein preparation module in the MOE software [10]. The checked protein was processed via the Maestro Protein Preparation Wizard in order to set up protonation states and partial charges on all protein atoms and also to remove any existing clashes [11,12]. The DHFR binding site was determined based on the coordinates of the co-crystallized inhibitor. A grid box was then generated via the glide receptor grid generation module [13].

Al ligands were prepared via the LigPrep module in order to assign partial charges and to generate a single low energy conformation [14]. Using glide all prepared ligands were docked into the previously prepared DHFR structure where the extra-precision (XP) algorithm was used for conformational sampling as well as scoring [13,15]. This extensive scoring function includes terms for Van der Waals, hydrogen bond, electrostatic interactions, desolvation penalty and penalty for intra-ligand contact. The best scoring pose of each ligand was selected for the final docking list. The binding mode picture of the best docked ligand was generated by MOE [16].

**Synthesis**

**Synthesis of 5-ethoxy-2-(prop-2-yn-1-ylsulfanyl)-1H-benzimidazole (AZ-0):** A mixture of 5-ethoxy-2-mercaptobenzimidazole (0.01 mole, 1.94 g), potassium carbonate anhydrous (>0.01 mole, 2 g) and acetonitrile (25 ml) has been heated and stirred under reflux for 30 min until the temperature reach 70ºC, then propargyl bromide (>0.01 mole, 2 ml) was added drop wise, the reacted mixture was heated and stirred under reflux for 3 hours. After cooling, the mixture was filtered so the insoluble residues were removed by filtration, and then the solvent was removed under reduced pressure to give a dark brown liquid. After that, 25 ml chloroform and 25 ml distilled water was added 3 times and the filtrate were extracted by using separatory funnel, the chloroform layers were collected, dried by using magnesium sulphate and evaporated under reduced pressure. A brown viscous mixture were collected (AZ-0): C12H12N2OS, 1.5 g, 77% yield, Mp: 115ºC -117°C, IR (KBr cm\(^{-1}\)), acetylenic C-H stretching (3280.32 cm\(^{-1}\)), C-H stretching Ar (3062.41 cm\(^{-1}\)), C≡C stretching (2117.46 cm\(^{-1}\)), C=C stretching Ar. (1419.35 cm\(^{-1}\)), C=N stretching (1614 cm\(^{-1}\)), C-N stretching aromatic ( 1272 cm\(^{-1}\)), S-C stretching (651.82 cm\(^{-1}\)), N-H stretching (3382.59 cm\(^{-1}\)), C-O-C stretching (1029.80 cm\(^{-1}\)), CH\(_3\) stretching aliphatic (2975.63 cm\(^{-1}\)), CH\(_2\) stretching aliphatic (2919.70 cm\(^{-1}\)), C-H out of plane bending Ar (8157.74 cm\(^{-1}\), 966.16 cm\(^{-1}\)), 1H-NMR (DMSO-d\(_6\)) : δ, 6.75-7.48 (m, 3H, Aromatic protons), 5.05 (s, 1H, NH), 4-4.1 (m, 2H, O-CH\(_2\) aliphatic), 1.38 (t, 3H, CH\(_3\)-CH\(_2\) aliphatic), 1.38-3.21 (s, 2H, S-CH\(_2\)-C), 2.51 (s, 1H, C≡CH).

**Synthesis of 5-ethoxy-2-{[4-(t-amino-1-yl)but-2-yn-1-ylsulfanyl)-1H-benzimidazole derivatives (AZ1-AZ6):** A mixture of 5-ethoxy-2-(prop-2-yn-1-ylsulfanyl)-1H-benzimidazole (AZ-0), paraformaldehyde (0.46 g, 0.01 mole in excess), the cyclic amine 0.01 mole (pyrrolidine, 2-methylpiperidine, 1-methylpiperazine, 2,6-dimethylpiperidine, azepane, morpholine), and a catalytic amount of cuprous chloride in 1, 4-dioxane (25 ml) was stirred at a room temperature for about 10 min then heated and stirred under reflux in a range between 70-75°C for about three hours. The resulted brown mixture was cooled, and then filtered to remove the insoluble residue and concentrated under a
reduced pressure to give a brown, semisolid product, which was dissolved in a least amount of diethyl ether, then filtered and concentrated under a reduced pressure. The final products were (AZ-1, AZ-2, AZ-3, AZ-4, AZ-5, and AZ-6).

5-ethoxy-2-[4-(pyrrolidin-1-yl)but-2-yn-1-yl][sulfanyl]-1H-benzimidazole (AZ-1): The titled compound was prepared following the similar procedure for the synthesis of 5-ethoxy-2-[4-(t-amino-1-yl)but-2-yn-1-yl][sulfanyl]-1H-benzimidazole derivatives (AZ1-AZ6) by Mannich reaction in 1.5 g yield 47%, mp: (89°C -91°C), FT-IR (KBr cm⁻¹): C-H stretching aromatic (3066.26 cm⁻¹), C-H stretching with tertiary amine (2339.23 cm⁻¹), C≡C stretching aromatic (1442.50 cm⁻¹), C≡N stretching (1617.38 cm⁻¹), C-N tertiary cyclic amine (1145.51 cm⁻¹), C-N stretching aromatic (1346.07 cm⁻¹), C-O-C stretching (1039.44 cm⁻¹), N-H stretching (3393.96 cm⁻¹), C-H stretching aliphatic (2938.98 cm⁻¹), CH₃ stretching aliphatic (2798.21 cm⁻¹), C-H out of plane bending aromatic (962.31 cm⁻¹, 827.31 cm⁻¹, 711.60 cm⁻¹), 1H-NMR (DMSO-d₆): δ, 1.33-1.37 (t, 3H, CH₂-CH₃ aliphatic), 1.64-2.72 (m, 8H), 3.31-3.34 (s, 2H, C-CH₂-N), 3.57 (s, 2H, S-CH₂-C), 4-4.17 (m, 2H, O-CH₂ aliphatic), 5.07 (s, 1H, NH), 6.78-7.47 (m, 3H, aromatic proton), 13C-NMR (DMSO d₆): δ, 15.16 ppm (5-Ethoxy-2-MBI), 23.54 ppm (SCH₂), 23.68 ppm (cyclic amine carbons), 42.72 ppm (CH₃N), 52.14, 64.09 ppm, 78.36 ppm (C≡C), 79.9 ppm, 102.05 ppm, 110.7 ppm,112.23 ppm, 130.52 ppm, 137.81 ppm, 147.8 ppm, 154.96 ppm. Elemental analysis: C₁₉H₂₅N₃OS, Calcd: C, 66.37%; H, 7.27%; N, 12.22%; Found: C, 66.54%; H, 7.64%; N, 13.31%. Found: C, 64.41%; H, 6.44%; N, 13.04%.

5-ethoxy-2-[4-(2-methylpiperidin-1-yl)but-2-yn-1-yl][sulfanyl]-1H-benzimidazole (AZ-2): The titled compound was prepared following the similar procedure for the synthesis of 5-ethoxy-2-[4-(t-amino-1-yl)but-2-yn-1-yl] sulfanyl]-1H-benzimidazole derivatives (AZ1-AZ6) by Mannich reaction in 2.3 g yield 67%, mp: (105°C - 108°C), FT-IR (KBr cm⁻¹): C-H stretching aromatic (3046.98 cm⁻¹), C-H stretching with tertiary amine (2359.59 cm⁻¹), C≡C stretching aromatic (1452.14 cm⁻¹), C≡N stretching (1617.38 cm⁻¹), C-N stretching tertiary cyclic amine (1145.51 cm⁻¹), C-N stretching aromatic (1346.07 cm⁻¹), C-O-C stretching (1039.44 cm⁻¹), N-H stretching (3393.96 cm⁻¹), CH₃ stretching aliphatic (2944.77 cm⁻¹), CH₂ stretching aliphatic (2809.78 cm⁻¹), C-H out of plane bending aromatic (958.45 cm⁻¹, 815.74 cm⁻¹). 1H-NMR (DMSO-d₆): δ, 1.33-1.37 (t, 3H, CH₂-CH₃ aliphatic), 1.1-2.5 (m, 12H), 3.14-3.3 (s, 2H, C-CH₂-N), 3.4-3.57 (m, 2H, S-CH₂-C), 4-4.17 (m, 2H, O-CH₂ aliphatic), 5.08 (s, 1H, NH), 6.78-7.47 (m, 3H, aromatic proton), 13C-NMR (DMSO d₆): δ, 15.15 ppm, 17.41 ppm (cyclic amine CH₃ carbons), 22.23 ppm (SCH₂), 22.42 (cyclic amine carbons), 25.48 ppm, 33.53 ppm, 43.81 ppm (CH₃N), 50.92 ppm, 54.41 ppm, 64.14 ppm, 79.19 ppm, 79.35 ppm, 102.17 ppm, 110.8 ppm, 112.34 ppm, 130.52 ppm, 137.81 ppm, 147.8 ppm, 154.96 ppm. Elemental analysis: C₁₇H₂₁N₃OS, Calcd: C, 64.67%; H, 6.65%; N, 11.98%; Found: C, 66.41%; H, 6.44%; N, 13.04%.

5-ethoxy-2-[4-(4-methylpiperazin-1-yl)but-2-yn-1-yl][sulfanyl]-1H-benzimidazole (AZ-3): The titled compound was prepared following the similar procedure for the synthesis of 5-ethoxy-2-[4-(t-amino-1-yl)but-2-yn-1-yl] sulfanyl]-1H-benzimidazole derivatives (AZ1-AZ6) by Mannich reaction in 2.2 g yield 63%, FT-IR (KBr cm⁻¹): C-H stretching aromatic (3075.91 cm⁻¹), C-H stretching with tertiary amine (2339.14 cm⁻¹), C≡C stretching aromatic (1448.28 cm⁻¹), C≡N stretching (1699.41 cm⁻¹), C-N tertiary cyclic amine (1180.22 cm⁻¹, 1110.80 cm⁻¹), C-N stretching aromatic (1346.07 cm⁻¹), C-O-C stretching (1006.64 cm⁻¹), N-H stretching (3399.89 cm⁻¹), C-H stretching aliphatic (2944.77 cm⁻¹), CH₂ stretching aliphatic (2798.21 cm⁻¹), C-H out of plane bending aromatic (941.09 cm⁻¹, 815.74 cm⁻¹). 1H-NMR (DMSO-d₆): δ, 1.33-1.36 (t, 3H, CH₂-CH₃ aliphatic), 1.1-2.5 (m, 12H), 3.14-3.3 (s, 2H, C-CH₂-N), 3.4-3.57 (m, 2H, S-CH₂-C), 4-4.18 (m, 2H, O-CH₂ aliphatic), 5.08 (s, 1H, NH), 6.78-7.48 (m, 3H, aromatic proton), 13C-NMR (DMSO d₆): δ, 15.17 ppm, 22.18 ppm (SCH₂), 45.11 ppm (cyclic amine CH₂ carbon), 46.53 ppm (CH₃N), 51.37 ppm, 54.37 ppm (cyclic amine carbons), 64.06 ppm, 79.15 ppm, 80.03 ppm (C≡C), 102.08 ppm, 110.72 ppm, 112.34 ppm, 131.71 ppm, 137.79 ppm, 149.38 ppm, 155.11 ppm (5-Ethoxy-2-MBI). Elemental analysis: C₁₉H₂₅N₃OS, Calcd: C, 67.36%; H, 7.27%; N, 12.22%; Found: C, 66.54%; H, 7.64%; N, 11.98%.

5-ethoxy-2-[4-(2,6-dimethylpiperidin-1-yl)but-2-yn-1-yl][sulfanyl]-1H-benzimidazole (AZ-4): The titled compound was prepared following the similar procedure for the synthesis of 5-ethoxy-2-[4-(t-amino-1-yl)but-2-yn-1-yl][sulfanyl]-1H-benzimidazole derivatives (AZ1-AZ6) by Mannich reaction in 1.9 g yield 53%, FT-IR (KBr cm⁻¹): C-H stretching aromatic (3089.58 cm⁻¹), C-H stretching with tertiary amine (2264.02 cm⁻¹), C≡C stretching aromatic (1430.92 cm⁻¹), C≡N stretching (1627.63 cm⁻¹), C-N tertiary cyclic amine (1180.22 cm⁻¹, 1110.80 cm⁻¹), C-N stretching aromatic (1328.71 cm⁻¹), C-O-C stretching (1099.44 cm⁻¹), N-H stretching (3201.26 cm⁻¹), CH₂ stretching aliphatic (2925.48 cm⁻¹), CH₃ stretching aliphatic (2856.06 cm⁻¹), C-H out of plane bending aromatic (952.66 cm⁻¹, 809.96 cm⁻¹, 728.96 cm⁻¹). 1H-NMR (DMSO-d₆): δ, 1.12-2.5 (m, 14H), 1.32-1.35 (t, 3H, CH₂-CH₃ aliphatic), 3.32-3.42 (s, 2H, C-CH₂-N), 3.5-3.57 (s, 2H, S-CH₂-C), 4-4.15 (m, 2H, O-CH₂ aliphatic), 5.08 (s, 1H, NH), 6.8-7.45 (m,
5-ethoxy-2-[[4-(azepan-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole (AZ-5): The titled compound was prepared following the similar procedure for the synthesis of 5-ethoxy-2-[[4-(t-amino-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole derivatives (AZ1-AZ6) by Mannich reaction in 2 g, yield 58%, mp (118°C -119°C), FT-IR (KBr cm⁻¹): C-H stretching aromatic (3075.905 cm⁻¹), C-H stretching with tertiary amine (2350.80 cm⁻¹), C≡C stretching aromatic (1432.85 cm⁻¹), C≡N stretching (1604.48 cm⁻¹), C-N tertiary cyclic amine (1184.08 cm⁻¹), C-N stretching aromatic (1355.71 cm⁻¹), C-O-C stretching (1099.23 cm⁻¹), N-H stretching (3377.99 cm⁻¹), CH₃ stretching aliphatic (2910.06 cm⁻¹), CH₂ stretching aliphatic (2842.56 cm⁻¹), C-H out of plane bending aromatic (977.80 cm⁻¹, 802.24 cm⁻¹, 711.60 cm⁻¹). 1H-NMR (DMSO-d₆): δ, 1.34-1.37 (t, 3H, CH₃-CH₂ aliphatic), 3.02 (s, 2H, C-CH₂-N), 3.26-3.36 (s, 2H, S-CH₂-C), 4-4.16 (m, 2H, O-CH₂ aliphatic), 5.06 (s, 1H, NH), 6.8-7.47 (m, 3H, aromatic proton). Elemental analysis: C₁₀H₁₃N₃O₃S, Calcd: C, 66.37%; H, 6.97%; N, 12.30%. Found: C, 66.40%; H, 6.97%; N, 12.30%.

5-ethoxy-2-[[4-(morpholin-4-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole (AZ-6): The titled compound was prepared following the similar procedure for the synthesis of 5-ethoxy-2-[[4-(t-amino-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole derivatives (AZ1-AZ6) by Mannich reaction in 1.7 g, yield 51%, mp (129°C-131°C), FT-IR (KBr cm⁻¹): C-H stretching aromatic (3075.91 cm⁻¹), C-H stretching with tertiary amine (2335.37 cm⁻¹), C≡C stretching aromatic (1452.14 cm⁻¹), C≡N stretching (1612.20 cm⁻¹), C-N tertiary cyclic amine (1268.99 cm⁻¹, 1128.16 cm⁻¹), C-N stretching aromatic (1336.43 cm⁻¹), C-O-C stretching (1006.66 cm⁻¹), N-H stretching (3409.59 cm⁻¹), CH₃ stretching aliphatic (2923.56 cm⁻¹), CH₂ stretching aliphatic (2825.20 cm⁻¹), C-H out of plane bending aromatic (850.45 cm⁻¹, 792.6 cm⁻¹). 1H-NMR (DMSO-d₆): δ, 1.33-1.37 (t, 3H, CH₃-CH₂ aliphatic), 2.2, 2.4, 2.5 (m, 8H), 3.46-3.57 (s, 2H, S-CH₂-C), 4-4.19 (m, 2H, O-CH₂ aliphatic), 6.8-7.48 (m, 3H, aromatic proton), 5.09 (s, 1H, NH). Elemental analysis: C₁₀H₂₃N₃O₂S, Calcd: C, 61.55%; H, 6.33%; N, 12.67%. Found: C, 61.25%; H, 6.68%; N 12.95%.

Docking Results

Docking results were shown in Table 1 and Figure 3.

Table 1 The Glide XP scores of docked compounds

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Grid XP Score (kcal/mol)</th>
<th>Number of heavy atoms</th>
<th>Ligand efficiency (kcal/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZ-1</td>
<td>-7.04</td>
<td>22</td>
<td>-0.32</td>
</tr>
<tr>
<td>AZ-2</td>
<td>-5.18</td>
<td>24</td>
<td>-0.216</td>
</tr>
<tr>
<td>AZ-3</td>
<td>-5.6</td>
<td>24</td>
<td>-0.233</td>
</tr>
<tr>
<td>AZ-4</td>
<td>-5.54</td>
<td>24</td>
<td>-0.231</td>
</tr>
<tr>
<td>AZ-5</td>
<td>-5.28</td>
<td>23</td>
<td>-0.23</td>
</tr>
<tr>
<td>AZ-6</td>
<td>-6.68</td>
<td>25</td>
<td>-0.23</td>
</tr>
<tr>
<td>Co-crystallized ligand</td>
<td>-10.24</td>
<td>32</td>
<td>-0.32</td>
</tr>
</tbody>
</table>

Kadhim, et al. Culture Media
Mueller Hinton agar (MHA) (Mastgrp Ltd, UK)/(HiMedia, India), Mueller Hinton broth (MHB) (Mastgrp Ltd, UK), Sabouraud dextrose agar (SDA) (Mastgrp Ltd, UK), Sabouraud dextrose broth (SDB) (HiMedia, India).

Test Microorganisms
Staphylococcus aureus (S. aureus ATCC® 6538™), Bacillus subtilis (B. Subtilis ATCC® 6633™), Pseudomonas aeruginosa (P. aeruginosa ATCC® 9027™), Escherichia coli (E. coli ATCC® 8739™), and Candida albicans (C. albicans ATCC® 10231™), all these pure cultures of bacterial strains were obtained from Dar Al Dawa (Na’ur, Jordan).

Antimicrobial Activity Evaluation
The antimicrobial activity of the newly synthesized compounds 5-ethoxy-2-[(4-(pyrrolidin-1-yl)but-2-yn-1-yl)sulfanyl]-1H-benzimidazole (AZ-1) with the DHFR active site. Hydrogen bonding is shown as orange dotted lines whereas intramolecular cation-π interactions are shown as blue dotted lines

Figure 3 The binding mode of 5-ethoxy-2-[(4-(pyrrolidin-1-yl)but-2-yn-1-yl)sulfanyl]-1H-benzimidazole (AZ-1) with the DHFR active site. Hydrogen bonding is shown as orange dotted lines whereas intramolecular cation-π interactions are shown as blue dotted lines.
incubated for 24 hours at 37°C for bacteria and for 48 hours at 25°C for fungi. The determination of MIC was done by comparing the turbidity of the positive control with the turbidity of each tested tube. MIC tube was having the lowest concentration of the compound in which no turbidity was observed.

The minimum bactericidal/fungicidal concentration (MBC/MFC) is the lowest concentration of antimicrobial agent required to kill the microorganism [18]. The determination of minimum bactericidal/fungicidal concentration (MBC/MFC) was done by sub-culturing the MIC tube and the tubes with concentration more than MIC on MHA/SDA using sterile swabs, the plates were incubated for 24 hours at 37°C for bacteria and for 48 hours at 25°C for fungi. The test tube having the lowest concentration which gave no growth was the MBC/MFC, the test were performed in triplicates.

**Statistical Analysis**

Statistical analysis was carried by using statistical packages for social science software (SPSS version 21) for student’s t-test. Values are expressed as mean ± SD.

**RESULTS**

**Antimicrobial Activity**

The newly synthesized compounds (AZ1-AZ6) showed antimicrobial activity against all types of microorganisms being tested (Tables 2 and 3). After 24 hours incubation at 37°C for bacteria and after 48 hours incubation at 25°C for fungi, the zone of inhibition diameter and the minimum inhibitory concentration (MIC) were determined. Compounds 5-ethoxy-2-{[4-(pyrrolidin-1-yl)but-2-yn-1-yl]sulfanyl}-1H-benzimidazole (AZ-1), 5-ethoxy-2-{[4-(4-methylpiperazin-1-yl)but-2-yn-1-yl]sulfanyl}-1H-benzimidazole (AZ-3), 5-ethoxy-2-{(2,6-dimethylpiperidin-1-yl)but-2-yn-1-yl]sulfanyl}-1H-benzimidazole (AZ-4), 5-ethoxy-2-{[4-(azepan-1-yl)but-2-yn-1-yl]sulfanyl}-1H-benzimidazole (AZ-5), and 5-ethoxy-2-{[4-(morpholin-4-yl)but-2-yn-1-yl]sulfanyl}-1H-benzimidazole (AZ-6) exhibited the highest antibacterial activity against *B. subtilis* with lowest MIC value 31.25 µg/ml, all the synthesized compounds did not exhibited zone of inhibition at a concentration of 31.25 µg/ml against *B. subtilis*. Compounds 5-ethoxy-2-{[4-(pyrrolidin-1-yl)but-2-yn-1-yl]sulfanyl}-1H-benzimidazole (AZ-1), 5-ethoxy-2-{[4-(4-methylpiperazin-1-yl)but-2-yn-1-yl]sulfanyl}-1H-benzimidazole (AZ-3), and 5-ethoxy-2-{[4-(morpholin-4-yl)but-2-yn-1-yl]sulfanyl}-1H-benzimidazole (AZ-6) revealed the highest antibacterial activity against *S. aureus* with lowest MIC value of 125 µg/ml and zone of inhibition diameter of 10.5 ± 2.1 mm at concentration 125 µg/ml for (AZ-1) and 11 ± 2.8 mm at concentration of 125 µg/ml for (AZ-3), while compound (AZ-6) did not showed zone of inhibition. All the synthesized compounds showed the same antibacterial activity against *E. coli* and *P. aeruginosa* with MIC values of (500 µg/ml, 250 µg/ml) respectively. Compound 5-ethoxy-2-{[4-(2,6-dimethylpiperidin-1-yl)but-2-yn-1-yl]sulfanyl}-1H-benzimidazole (AZ-4) showed the best antifungal activity against *C. albicans* with the lowest MIC value of 31.25 µg/ml and zone of inhibition diameter of 6 ± 1.4 mm.

For MBC values, all the synthesized derivatives showed the same MBC value (62.5 µg/ml) against *B. subtilis* except compound 5-ethoxy-2-{[4-(2-methylpiperidin-1-yl)but-2-yn-1-yl]sulfanyl}-1H-benzimidazole (AZ-2) which exhibited the highest MBC value of 500 µg/ml. All the synthesized compounds had the same values against *E. coli* and *P. aeruginosa*, the MBC value against *E. coli* was (1000 µg/ml) compared to the standard (ciprofloxacin) which showed MBC value of (125 µg/ml), while against *P. aeruginosa* the value was 500 µg/ml, while the positive control showed MBC value of 250 µg/ml. All the MBC values against bacteria were higher than the standard ciprofloxacin. For *C. albicans*, compound (AZ-4) exhibited MFC value of 62.5 µg/ml, which was the same as the MFC value for the positive control (fluconazole). All synthesized compounds (AZ1-6) exhibited good antibacterial and antifungal activity.

**Table 2 The zone of inhibition diameter (in mm) of the synthesized compounds (AZ1-AZ6) at 500 µg/ml concentration**

<table>
<thead>
<tr>
<th>Compound</th>
<th><em>P. aeruginosa</em> mean ± SD</th>
<th><em>E. coli</em> mean ± SD</th>
<th><em>S. aureus</em> mean ± SD</th>
<th><em>B. subtilis</em> mean ± SD</th>
<th><em>C. albicans</em> mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentration</td>
<td>500 µg/ml</td>
<td>500 µg/ml</td>
<td>500 µg/ml</td>
<td>500 µg/ml</td>
<td>500 µg/ml</td>
</tr>
<tr>
<td>AZ-1</td>
<td>7.5 ± 2.1</td>
<td>6.5 ± 2.1</td>
<td>12.5 ± 2.1</td>
<td>15.5 ± 0.7</td>
<td>13 ± 0</td>
</tr>
<tr>
<td>AZ-2</td>
<td>8 ± 2.8</td>
<td>9 ± 1.4</td>
<td>17 ± 0.7</td>
<td>12.5 ± 2.1</td>
<td>17.5 ± 2.1</td>
</tr>
<tr>
<td>AZ-3</td>
<td>-</td>
<td>-</td>
<td>17.5 ± 2.1</td>
<td>12 ± 1.4</td>
<td>17 ± 0</td>
</tr>
<tr>
<td>AZ-4</td>
<td>-</td>
<td>-</td>
<td>8.5 ± 2.1</td>
<td>14.5 ± 0.7</td>
<td>21 ± 2.8</td>
</tr>
<tr>
<td>AZ-5</td>
<td>-</td>
<td>-</td>
<td>10 ± 1.4</td>
<td>14.5 ± 0.7</td>
<td>14.5 ± 0.5</td>
</tr>
</tbody>
</table>
Ciprofloxacin (5 µg/ml) & 28 ± 1.4 & 26.5 ± 2.1 & 22.5 ± 2.1 & 24 ± 2.8 & -  
Fluconazole (500 µg/ml) & - & - & - & - & 25 ± 1.4  
Negative control & - & - & - & - & -  
Values are mean ± SD (n=3), (-): no growth  
AZ-1: 5-ethoxy-2-[[4-(pyrrolidin-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole;  
AZ-2: 5-ethoxy-2-[[4-(2-methylpiperidin-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole;  
AZ-3: 5-ethoxy-2-[[4-(4-methylpiperazin-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole;  
AZ-4: 5-ethoxy-2-[[4-(2,6-dimethylpiperidin-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole;  
AZ-5: 5-ethoxy-2-[[4-(azepan-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole;  
AZ-6: 5-ethoxy-2-[[4-(morpholin-4-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole

**Table 3** The minimum inhibitory concentration (MIC) of the synthesized compounds (AZ1-AZ6) in µg/ml against *S. aureus, B. subtilis, E. coli, P. aeruginosa* and *C. albicans*

<table>
<thead>
<tr>
<th>Compound</th>
<th><em>P. aeruginosa</em></th>
<th><em>E. coli</em></th>
<th><em>S. aureus</em></th>
<th><em>B. subtilis</em></th>
<th><em>C. albicans</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentration</td>
<td>MIC/MBC (µg/ml)</td>
<td>MIC/MBC (µg/ml)</td>
<td>MIC/MBC (µg/ml)</td>
<td>MIC/MBC (µg/ml)</td>
<td>MIC/MBC (µg/ml)</td>
</tr>
<tr>
<td>AZ-1</td>
<td>250/500</td>
<td>500/1000</td>
<td>125/250</td>
<td>31.25/62.5</td>
<td>250/500</td>
</tr>
<tr>
<td>AZ-2</td>
<td>250/500</td>
<td>500/1000</td>
<td>500/1000</td>
<td>250/500</td>
<td>125/500</td>
</tr>
<tr>
<td>AZ-3</td>
<td>250/500</td>
<td>500/1000</td>
<td>125/250</td>
<td>31.25/62.5</td>
<td>62.5/125</td>
</tr>
<tr>
<td>AZ-4</td>
<td>250/500</td>
<td>500/1000</td>
<td>500/1000</td>
<td>31.25/62.5</td>
<td>31.25/62.5</td>
</tr>
<tr>
<td>AZ-5</td>
<td>250/500</td>
<td>500/1000</td>
<td>500/1000</td>
<td>31.25/62.5</td>
<td>125/250</td>
</tr>
<tr>
<td>AZ-6</td>
<td>250/500</td>
<td>500/1000</td>
<td>125/250</td>
<td>31.25/62.5</td>
<td>125/250</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>125/250</td>
<td>62.5/125</td>
<td>62.5/125</td>
<td>15.6/31.25</td>
<td>-</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Negative control</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

AZ-1: 5-ethoxy-2-[[4-(pyrrolidin-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole;  
AZ-2: 5-ethoxy-2-[[4-(2-methylpiperidin-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole;  
AZ-3: 5-ethoxy-2-[[4-(4-methylpiperazin-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole;  
AZ-4: 5-ethoxy-2-[[4-(2,6-dimethylpiperidin-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole;  
AZ-5: 5-ethoxy-2-[[4-(azepan-1-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole;  
AZ-6: 5-ethoxy-2-[[4-(morpholin-4-yl)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole. MIC: Minimum Inhibitory Concentration, MBC: Minimum Bactericida Concentration, MFC: Minimum Fungicidal Concentration

**DISCUSSION**

Chemistry

The designed compounds were prepared as shown in Figures 4 and 5. Figure 4 involved direct nucleophilic displacement by the anionic sulfur in the 2-mercaptopbenzimidazole to bromide on the β carbon of the propargyl bromide to generate 5-ethoxy-2-(prop-2-yn-1-ylsulfanyl)-1H-benzimidazole (AZ-0). The Mannich reaction of 2-(prop-2-yn-1-ylsulfanyl)-1,3-benzothiazole AZ-0, paraformaldehyde, appropriate cyclic amines, and a catalytic amount of cuprous chloride in peroxide-free 1,4-dioxane was heated at 70-75°C to yield the designed compounds (AZ1-AZ6).

**Figure 4 Alkylation reaction of 5-ethoxy-2-MBI**

The yield obtained ranged from 47% to 67% as semi solid products. The proposed mechanism for Mannich reaction is shown in Figure 5, the mechanism first showed the formation of the Schiff base from condensation of formaldehyde and the appropriate cyclic amine. The attack of the acetylenic carbanion on the Schiff base and the migration of the double bond to the nitrogen resulted in the final products (AZ1-AZ6). These structures were verified through FT-IR, 1H-NMR, 13C-NMR, and elemental analysis.
Docking our compounds along with the co-crystallized ligand into the DHFR enzyme active pocket has resulted in energetically favorable binding energies (Table 1). Compound 1 (Glide-XP score=-7.04 kcal/mol) had the lowest docking score, although it was higher than the co-crystallized inhibitor (Glide-XP score=-10.24 kcal/mol). However, analyzing compounds docking scores in relationship with their size, compound AZ-1 was able to obtain as good ligand efficiency score (0.32 kcal/mol) as the co-crystallized ligand. As shown in Figure 3, compound AZ-1 was able to adopt a U-shape conformation that fits nicely on the DHFR active site. Such a conformation was assisted by the intra-molecular interactions formed between the pyrrolidine protonated amine and the bicyclic aromatic system. Compound AZ-1 was able to make hydrogen bonding with the backbone amide of Leu22 and multiple vdW contacts with surrounding hydrophobic residues (e.g. Ile07, Leu22, Phe34, Ile60 and Val115). These compounds, particularly compound 1, are predicted to be good binders to the DHFR enzyme and could potentially act as a good starting point for future antibacterial agents.

**Antimicrobial Activity**

The evaluation of the antimicrobial activity of the newly synthesized compounds was through agar diffusion test and broth dilution test for MIC determination as they are the most common method used in evaluating the antimicrobial activity [18], the results of the agar diffusion method and the broth dilution method were variable [19]. The variability of the results using the agar diffusion method and the MIC method may be due to the selectivity of the 5-ethoxy-2-[4-(t-cyclic amine)but-2-yn-1-yl]sulfanyl]-1H-benzimidazole derivatives (AZ1-AZ6), and their general reactivity, resulted in reporting a low antimicrobial activity against some microorganisms especially *E. coli* and *P. aeruginosa* (gram negative bacteria), because of their low solubility in water that made their diffusion in agar medium weak, so the accuracy of agar diffusion is unsatisfactory. The results are frequently inadequate in comparison with the results of the broth dilution test that lack these difficulties [17].

The best antifungal activity against *C. albicans* was (AZ-4), which gave antifungal activity similar to the positive control antifungal activity, this activity may attributed to the flexibility enlargement of the cyclic amine (AZ-4), electronegativity, lipophilicity, ionic nature, and the appropriate distance between ionic head aryl imidazole and cyclic amine in these compounds. The proposed mechanism for the antifungal selectivity of these compounds was through inhibition of CA-CYP51 resulted in blocking of the ergosterol formation due to the inhibition of lanosterol 14-α-demethylase that facilitate permeability through the cell membrane, which was the same mechanism of action of the positive control (flucanozole) [20].

All synthesized compounds showed better antibacterial activity against gram positive than gram negative bacteria, which may be due to the differences in the cell wall structures, causing greater inhibition of cell growth in gram positive bacteria [17]. The difference between them in the nature of peptidoglycan layer, in which the cell wall of gram positive bacteria were more receptive to the synthesized compounds, due to the absence of outer membrane, while gram-negative bacteria showed greater resistance, associated with the presence of the outer membrane that contain phospholipids bilayer, pore-forming proteins and lipopolysaccharides (LPS), which hinders access to the bacterial inner membrane, which is the probable cellular target of the compound.

These synthesized compounds showed antibacterial activity against *B. subtilis* better than the antibacterial activity against *S. aureus*, which may be due to the virulence nature and high resistance of *S. aureus*. All the synthesized compounds gave good antimicrobial activity against *B. subtilis* with MIC value 31.25 µg/ml, except (AZ-2) which showed MIC value of 250 µg/ml as showed in Table 2, this may be due to the steric factor generated by the methyl
group neighboring basic cyclic amine of 2-methylpiperidinedine. The diffusion of these compounds through the cell wall is facilitated due to their good lipophilicity, which play important role in facilitating the passage through the cell wall of gram positive bacteria. Surprisingly, the antimicrobial activity of the synthesized compound against *P. aeruginosa* was better than the antimicrobial activity against *E. coli*, which may be attributed to the good permeability of the synthesized compounds through *P. aeruginosa* outer membrane by dual pathway (porins and phospholipids bilayer), in which *E. coli* lacks porins in the outer membrane, for that with *E. coli* the synthesized compounds used only one pathway for entering into *E. coli* bacterial cell, resulted in decreasing the accumulation of the compounds inside bacteria thus decreasing their antimicrobial activity [21].

**CONCLUSION**

We have reported the synthesis of novel series of amino acetylenic 5-ethoxy-2-mercaptobenzimidazole derivatives. A unique amino acetylenic side chain provides additional forces of interaction with various microorganisms. These amino acetylenic 5-ethoxy-2-mercaptobenzimidazole derivatives showed effective binding with DHFR as seen from the docking results and showed promising antimicrobial activity against fungi and against gram positive bacteria better than the antimicrobial activity against gram negative bacteria. Compound AZ-4 showed the highest antifungal activity against *C. albicans* with MIC value of 31.25 µg/ml which is similar to the antifungal activity of fluconazol. Future research, structural modifications are required for enhancing both antibacterial and antifungal activity, and selectivity to either pure antifungal agent.

**DECLARATIONS**

Conflict of Interest

The authors have disclosed no conflict of interest, financial or otherwise.

Acknowledgement

The authors would like to thank the University of Petra, Faculty of pharmacy for providing the necessary facilities to carry out this work.

**REFERENCES**


